|
rs1801282
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We have studied the association between single nucleotide polymorphisms in the interleukin (IL)-6 (-174 G>C), IL8 (-251T>A), tumor necrosis factor alpha (-308G>A), and PPARG (Pro12Ala) genes and the risk of CRC in a group of 377 cases and 326 controls from Barcelona, Spain.
|
12839942 |
2003 |
|
rs1805192
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We have studied the association between single nucleotide polymorphisms in the interleukin (IL)-6 (-174 G>C), IL8 (-251T>A), tumor necrosis factor alpha (-308G>A), and PPARG (Pro12Ala) genes and the risk of CRC in a group of 377 cases and 326 controls from Barcelona, Spain.
|
12839942 |
2003 |
|
rs3856806
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Compared with those individuals with the CC allele, increasing risk of CRC with increasing red meat intake was more pronounced among individuals with T alleles of PPARγC161T (rs3856806), but the association was not significant.
|
30489355 |
2019 |
|
rs3856806
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The stratified analysis revealed that the <i>PPARG</i> r</span>s3856806 C>T polymorphism also increased the risk of CRC, especially in male, ≥61 years old, never smoking, never drinking, BMI ≥ 24 kg/m<sup>2</sup>, colon cancer and rectum cancer subgroups.
|
30838172 |
2019 |
|
rs3856806
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Several studies evaluated the association between peroxisome proliferators-activated receptor gamma (PPARγ) Pro12Ala (rs1801282), and His477His (rs3856806) polymorphisms and the risk of colorectal cancer (CRC).However, the results were not stable.
|
29970681 |
2018 |
|
rs3856806
|
|
|
0.040 |
GeneticVariation |
BEFREE |
On the contrary, two other SNPs, PLA2G2A c.435+230C>T and PPARG c.1431C>T (p.His477His), were associated with a decrease in CRC risk.
|
18992148 |
2008 |
|
rs9858822
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The association between rs9858822 in the PPARG gene and colorectal cancer was statistically significant at the end of the second stage (OR per allele = 1.36, Bonferroni-adjusted P = 0.045), based on the "effective" number of markers in stage II (n = 306).
|
24045924 |
2013 |